Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04761783 | BESPOKE Study of ctDNA Guided Immunotherapy | completed | — | 290 | Natera, Inc.INDUSTRY | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02773238 |
| FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging |
| completed |
| Phase 2 |
| 51 |
| University of WashingtonOTHER |
| 1 |
| Aug 14, 2024 |
| clinicaltrials |
| NCT04529564 | Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA) | completed | — | 106 | AstraZenecaINDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03371485 | AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 9 | Cancer Research UKOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04144608 | Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC(TOGATHER) | completed | Phase 2 | 40 | Yongchang ZhangOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05068427 | Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | completed | Phase 2 | 34 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05634551 | Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status | completed | — | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT01712217 | A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib | completed | Phase 1 / Phase 2 | 220 | Astex Pharmaceuticals, Inc.INDUSTRY | 5 | Aug 2, 2024 | clinicaltrials |
| NCT02443324 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | completed | Phase 1 | 175 | Eli Lilly and CompanyINDUSTRY | 6 | Jul 31, 2024 | clinicaltrials |
| NCT03689855 | Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC(RamAtezo-1) | completed | Phase 2 | 21 | Washington University School of MedicineOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06521034 | First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer(Helpful) | completed | Phase 1 / Phase 2 | 124 | Yongchang ZhangOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03819387 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | completed | Phase 1 | 49 | Nitto BioPharma, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06516796 | Omitting of Lymphadenectomy is Acceptable for Lung Cancer Smaller Than 6 mm in Solid Size | completed | — | 2,713 | Liang ChenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517485 | First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b | completed | Phase 1 | 142 | Mersana TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT03485326 | A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients | completed | — | 1,700 | AstraZenecaINDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04194203 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | completed | Phase 3 | 305 | Hoffmann-La RocheINDUSTRY | 1 | Jul 19, 2024 | clinicaltrials |
| NCT04732520 | Feasibility Study of the Aliya System in the Treatment of Early Stage Non-small Cell Lung Cancer(INCITE ES) | completed | N/A | 47 | Galvanize Therapeutics, Inc.INDUSTRY | 3 | Jul 19, 2024 | clinicaltrials |
| NCT03195491 | A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia(CheckMate870) | completed | Phase 3 | 400 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 18, 2024 | clinicaltrials |
| NCT03560791 | A Review of Low-Dose CT Lung Cancer Screenings in a Community-Based Healthcare System With High Incidence(REACH) | completed | — | 7,659 | St Elizabeth HealthcareOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT04207775 | Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy(PISCES) | completed | — | 300 | AstraZenecaINDUSTRY | 1 | Jul 12, 2024 | clinicaltrials |
| NCT03091816 | Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer | completed | — | 15 | University of Southern CaliforniaOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT03681483 | RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer | completed | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT00254384 | Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery | completed | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT06378658 | A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants | completed | Phase 1 | 21 | BayerINDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03502330 | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | completed | Phase 1 | 42 | Yale UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06360211 | A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants | completed | Phase 1 | 15 | BayerINDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04480372 | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | completed | Phase 2 | 68 | Swiss Cancer InstituteOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT01513174 | Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone(GOAL) | completed | Phase 1 / Phase 2 | 186 | Spanish Lung Cancer GroupOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06221475 | A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants | completed | Phase 1 | 8 | BayerINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04740047 | Cios Mobile 3D Spin for Robotic Bronchoscopy | completed | — | 38 | Mayo ClinicOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06232967 | PPIO-006 Primary Tumor Resection for IVa NSCLC | completed | — | 223 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06294561 | TGRX-326 Pharmacokinetic Drug Interaction | completed | Phase 1 | 34 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03743051 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 7 | Jun 26, 2024 | clinicaltrials |
| NCT03743064 | A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 318 | Helsinn Healthcare SAINDUSTRY | 8 | Jun 26, 2024 | clinicaltrials |
| NCT04642469 | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.(MERMAID-2) | completed | Phase 3 | 30 | AstraZenecaINDUSTRY | 25 | Jun 25, 2024 | clinicaltrials |
| NCT03693300 | A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 117 | AstraZenecaINDUSTRY | 6 | Jun 18, 2024 | clinicaltrials |
| NCT03950674 | Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | completed | Phase 3 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02759835 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03847519 | Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 24 | Advaxis, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03497767 | A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases(OUTRUN) | completed | Phase 2 | 40 | Trans Tasman Radiation Oncology GroupOTHER | 2 | May 31, 2024 | clinicaltrials |
| NCT03022500 | Pulmonary sarcomatoid_MEDI4736+Treme | completed | Phase 2 | 32 | Seoul National University HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 15, 2024source: clinicaltrials